![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Top Stories in Nephrology 2024](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Top Stories in Nephrology 2024
USD21.48
USD52.48
Pay in 4 interest-free payments of $5.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Top Stories in Nephrology 2024](https://images.squarespace-cdn.com/content/v1/535bcb2fe4b05fe61b320c51/ff763443-50b9-464e-8c57-8a57698eb810/image7.png)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Top Stories in Nephrology 2024](https://s3.amazonaws.com/production.scholastica/public/attachments/9c499677-aa6b-4e1e-9360-4d7e41721fd8/large/figure_1._mechanism_of_synthesis_of_glp-1.png)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Top Stories in Nephrology 2024](https://velocityclinical.com/wp-content/uploads/2025/06/Rosesnstock-Lilly-Oral-GLP-1-Orforglipron-Lead-Investigator.jpg)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Top Stories in Nephrology 2024](https://www.researchgate.net/publication/407114666/figure/fig1/AS:11431282192134370@1781583549647/Abbreviations-GLP-1-RA-glucagon-like-peptide-1-receptor-agonist-n-number-of.png)
